Fresh from Blue Sky takeover, LakePharma signs antibody deal

Golden Gate Bridge

Private biotech Trianni and CRO LakePharma have penned a tech partnership to “empower antibody drug development.”

The agreement sees LakePharma gain the right to utilize the "Trianni Mouse Platform" for antibody discovery services, with the Californian CRO also being responsible for marketing the Trianni Platform as part of its service offerings in the US. Financial terms were not disclosed.

The Trianni Mouse Platform enables the expression of antibodies with fully human variable domains, leveraging in vivo selection to increase antibody diversity.

Virtual Event

Virtual Clinical Trials Online

This virtual event will bring together industry experts to discuss the increasing pace of pharmaceutical innovation, the need to maintain data quality and integrity as new technologies are implemented and understand regulatory challenges to ensure compliance.

“Trianni is excited to enter into this alliance with LakePharma,” said Matthias Wabl, the biotech's chairman and CEO. “We believe that the Trianni Platform, coupled with LakePharma’s robust antibody discovery and development service capabilities, will be an invaluable asset to clients seeking to develop antibody therapeutics.”

Hua Tu, chairman and CEO of LakePharma, added: “Bringing the Trianni Transgenic Mouse Platform in-house allows us to combine a world-class, novel technology with LakePharma’s unique immunization platform and screening strategies. We provide our clients with an unprecedented ability to conduct in vivo discovery of human monoclonal therapeutics in a proven combination of quality platforms.”

Sam Francisco-based Trianni currently focuses on antibody discovery platforms while LakePharma offers biologics discovery and development services.

In late March, LakePharma snapped up Massachusetts antibody CRO specialist Blue Sky BioServices for an undisclosed fee. The combined company saw it become the largest dedicated biologics CRO in the U.S., according to the firm.

-check out the release


Suggested Articles

Back in 2016, Pfizer signed up with CRO Icon to help it, alongside other CROs PPD and Parexel, run its vast trial network.

The EMA and FDA will need traditional clinical trial hurdles removed if governments want the inoculations as quickly as possible.

A new survey by Clinical Research IO has found that nearly one-quarter of polled trial investigators have stopped enrolling new patients.